AGN breakout after release of full Phase 2 data set for IPF! Solid breakout for Algernon Pharmaceuticals ($AGN.c $AGNPF) today, up 15% to $6.90 after reporting positive results from the full data set of its Phase II study of Ifenprodil for IPF and Chronic Cough, including statistically significant improvements in measures of cough!
Ifenprodil was well tolerated with a high overall compliance rate (average >90%) and no new safety concerns were identified.
AGN will be presenting the data to the US FDA alongside applying for orphan designation, the filing of a pre-IND application for a Phase 2b IPF with cough trial, and an application for Breakthrough Therapy designation.
https://themarketherald.ca/algernon-pharmaceuticals-reports-positive-results-of-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough-2022-09-01/